Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical trials and were only apparent from postmarketing surveillance data from the wider patient community.
This list is not limited to drugs that were ever approved by the FDA. Some of them (Lumiracoxib, Rimonabant, Tolrestat, Ximelagatran and Zimelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. LSD was never approved for marketing in the U.S or Europe.
Significant withdrawals
See also
- Adverse drug reaction
- Adverse events (AEs)
- European Medicines Agency
- Food and Drug Administration
References
External links
- CDER Report to the Nation: 2005 Has a list of U.S. withdrawals through 2005.
- Drug Recalls